Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a se...

Full description

Bibliographic Details
Main Authors: Babbs, A, Berg, A, Chatzopoulou, M, Davies, K, Davies, S, Edwards, B, Elsey, D, Emer, E, Figuccia, A, Fletcher, A, Guiraud, S, Harriman, S, Moir, L, Robinson, N, Rowley, J, Russell, A, Squire, S, Thomson, J, Tinsley, J, Wilson, F, Wynne, G
Format: Journal article
Language:English
Published: Elsevier 2019

Similar Items